Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended March 31,
	2024	2023
Biologics	37 %	34 %
Generics	18 %	20 %
Pharma	25 %	27 %
Contract-Manufactured Products	20 %	19 %
	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended March 31,
	2024	2023
High-Value Product Components	47 %	51 %
High-Value Product Delivery Devices	11 %	7 %
Standard Packaging	22 %	23 %
Contract-Manufactured Products	20 %	19 %
	100 %	100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended March 31,
	2024	2023
Americas	43 %	44 %
Europe, Middle East, Africa	48 %	47 %
Asia Pacific	9 %	9 %
	100 %	100 %

Schedule of Change in Contract With Customer, Asset and Liability

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:

	($ in millions)
Contract assets, December 31, 2023	$	21.5
Contract assets, March 31, 2024	19.9
Change in contract assets - (decrease) increase	$	(1.6)
Deferred income, December 31, 2023	$	(53.9)
Deferred income, March 31, 2024	(57.9)
Change in deferred income - (increase) decrease	$	(4.0)